<DOC>
	<DOCNO>NCT02278965</DOCNO>
	<brief_summary>The purpose study determine whether feasible give combination Metformin OMEGA-3 fatty acid one year woman history early stage breast cancer . We also evaluate whether metformin OMEGA-3 fatty acid combination cause change breast tissue , blood , mammogram .</brief_summary>
	<brief_title>Metformin Omega-3 Fatty Acids Woman With History Early Stage Breast Cancer</brief_title>
	<detailed_description>Metformin medication use treat prevent diabetes OMEGA-3 fatty acid show low cholesterol improve cardiovascular health . Research show Metformin OMEGA-3 fatty acid may also effective prevent cancer . In study , want find effect , good and/or bad , Metformin OMEGA-3 fatty acid combination risk develop new breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>History histologicallyconfirmed stage 0 , I , II , III breast carcinoma without evidence disease trial entry . Participants resect local recurrence eligible Minimum 6 month since last chemotherapy , biologic therapy ( i.e. , trastuzumab ) , radiation therapy , and/or breast surgery evidence recurrent disease Minimum 6 month since completion adjuvant tamoxifen ( tamoxifen know low mammographic density119121 ) . Current use third generation aromatase inhibitor [ AI ] ( i.e. , anastrozole , letrozole , exemestane ) permit provided participant stable dose past 6 month Age 21 75 year . Both pre postmenopausal woman include study . We exclude perimenopausal woman , define menstrual cycle irregularity ( variable cycle length differs normal 7 day ) FollicleStimulating Hormone ( FSH ) great 20 mili international unit Negative serum pregnancy test Normal mammogram contralateral breast within past 12 month , define new suspicious calcification abnormal finding warrant breast biopsy Eastern Cooperative Oncology Group ( ECOG ) performance status le 2 Participants must normal organ marrow function within 28 day prior randomization Body mass index ( BMI ) great equal 25 kilogram per meter square baseline fast glucose less 126 milligram per deciliter Participants must baseline mammographic density great equal 25 percent base upon Breast Imaging Reporting Data System ( BIRADS ) density score 2 , 3 , 4 . Women baseline mammographic density le 25 percent ( BIRADS Score= 1 ) eligible Willingness abstain omega3 fish oil supplement 30 day prior baseline evaluation study intervention Willingness comply study intervention followup procedure Ability understand willingness sign write informed consent document History histologicallyconfirmed bilateral breast cancer History plan bilateral mastectomy Evidence metastatic breast cancer Prior radiation therapy implant contralateral breast Known diabetes ( type 1 2 ) baseline fast glucose great 126 milligram per deciliter Any condition associate increase risk metforminassociated lactic acidosis ( e.g. , congestive heart failure define New York Heart Association [ NYHA ] Class III IV functional status , history acidosis type , intake 3 alcoholic beverage per day average past 6 month ) Currently take metformin , sulfonylurea , thiazolidinediones , insulin reason History allergic reaction attribute compound similar chemical biologic composition metformin omega3 fatty acid Receiving hormone replacement therapy , tamoxifen , raloxifene within 6 month trial entry Participants may receive investigational agent 30 day prior baseline evaluation study intervention Any omega3 fatty acid take 30 day prior baseline evaluation study intervention . If participant consume item would like participate study , 30day washout period require . Uncontrolled significant comorbid illness patient receive active chemotherapy radiotherapy ; psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Early Stage</keyword>
</DOC>